WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan 06 February 2011
Pfizer Reports Fourth-Quarter and Full-Year 2010 Results 01 February 2011
Pfizer Completes Tender Offer For Shares Of King Pharmaceuticals, Inc. 31 January 2011
Pfizer Submits Applications to Expand the Use of Prevnar 13® to Adults 50 and Older 22 December 2010
Pfizer Extends Tender Offer To Acquire King Pharmaceuticals, Inc. 15 December 2010
Young Children In Developing World Receive Accelerated Access to Pfizer's Prevenar 13 Vaccine 12 December 2010
Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib 06 December 2010
Pfizer Launches Global Centers for Therapeutic Innovation 18 November 2010
Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity 15 November 2010
Alpine Mountaineer and Alzheimer's Advocate to Climb Highest Peak on Each Continent 09 November 2010
Pfizer Reports Third-Quarter 2010 Revenues of $16.2 Billion 03 November 2010
Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066) 28 October 2010
Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil 22 October 2010
Biocon and Pfizer Enter Into Global Commercialization Agreement 20 October 2010
Results from a national survey of Alzheimer's Disease 15 October 2010
Pfizer to Acquire King Pharmaceuticals, Inc. 13 October 2010
Updated Pfizer Pipeline Focuses on Value, Unmet Medical Need 28 September 2010
Pfizer Commended For Leadership In Addressing Climate Change 22 September 2010
Pfizer to Acquire FoldRx Pharmaceuticals 02 September 2010
World Health Organization Grants Prequalification to Prevenar 13 24 August 2010
  • Start
  • Prev
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • Next
  • End

Business & Industry

  • GSK completes acquisition of Sierra Oncology
  • Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
  • Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
  • New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
  • Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

Research & Development

  • Inhalable COVID-19 vaccine shows promise in rodent model
  • Researchers discover new leukemia-killing compounds
  • Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
  • Biomarkers found that could be drug targets against a deadly form of brain cancer
  • COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
  • Novel drug combo activates natural killer cell immunity to destroy cancer cells
  • Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.